Chest
Volume 126, Issue 4, Supplement, October 2004, Page 807S
Journal home page for Chest

Poster Presentations
Efficacy of Advair Diskus 250/50 (Fluticasone Propionate/Salmeterol) or Ipratropium/Albuterol in Patients with COPD Associated with Chronic Bronchitis and/or Emphysema

https://doi.org/10.1378/chest.126.2_suppl_1.117SGet rights and content

Section snippets

Abstract

PURPOSE: Advair 250/50 via Diskus in COPD has been studied primarily in patients with COPD associated with chronic bronchitis (CB). This post hoc analysis evaluated treatment effects in patients with CB + emphysema or emphysema alone.

METHODS: Two multicenter, randomized, double-blind studies comparing the efficacy and safety of Advair 250/50 BID with ipratropium/albuterol 36/206 mcg QID (IB/ALB) over 8 weeks. Patients were identified by study investigators as having COPD associated with CB,

References (0)

Cited by (81)

  • Asthma and COPD: distinct diseases or components of a continuum?

    2023, Asthma in the 21st Century: New Research Advances
  • The Physiology of Asthma-Chronic Obstructive Pulmonary Disease Overlap

    2022, Immunology and Allergy Clinics of North America
View all citing articles on Scopus
View full text